Cytokinetics Stock Top Executives

CYTK
 Stock
  

USD 47.25  0.22  0.46%   

Cytokinetics employes about 253 people. The company is managed by 24 executives with total tenure of roughly 183 years, averaging almost 7.0 years of service per executive having 10.54 employees per reported executive. Assessment of Cytokinetics management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Cytokinetics future performance.
Continue to Trending Equities.
  
Refresh
  Robert Blum  CEO
CEO and President Director and Chief Executive of the Biopharmaceutical Concern
  Leonard Gage  Chairman
Independent Chairman of the Board
  Bradley Morgan  President
Senior Vice President - Drug Discovery and Early Development

Cytokinetics Return on Sales

(3.05)

Share

Cytokinetics Management Team Effectiveness

Cytokinetics has return on total asset (ROA) of (16.94) % which means that it has lost $16.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (120.54) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -63.24. The current Return on Average Assets is estimated to decrease to -0.33. The current Total Liabilities is estimated to increase to about 644.6 M. The current Current Liabilities is estimated to increase to about 77.5 M

Cytokinetics Quarterly Total Assets

856.25 Million

Share
The current Issuance Purchase of Equity Shares is estimated to increase to about 345.2 M, while Weighted Average Shares is projected to decrease to under 65.4 M.

Cytokinetics Workforce Comparison

Cytokinetics is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 506. Cytokinetics totals roughly 253 in number of employees claiming about 50% of stocks in Biotechnology industry.

Cytokinetics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytokinetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytokinetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cytokinetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Cytokinetics Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Cytokinetics Price Series Summation is a cross summation of Cytokinetics price series and its benchmark/peer.
.

Cytokinetics Notable Stakeholders

A Cytokinetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cytokinetics often face trade-offs trying to please all of them. Cytokinetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cytokinetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert Blum - CEO and President Director and Chief Executive of the Biopharmaceutical ConcernProfile
Leonard Gage - Independent Chairman of the BoardProfile
Bradley Morgan - Senior Vice President - Drug Discovery and Early DevelopmentProfile
Caryn McDowell - Chief Compliance Officer, Vice President General CounselProfile
Robert Wong - Chief Accounting Officer, Vice PresidentProfile
Sharon Barbari - CFO, Executive Vice President - FinanceProfile
Peter Roddy - Senior Vice President Chief Accounting OfficerProfile
Mark Schlossberg - Senior Vice President Legal and General CounselProfile
Elisabeth Schnieders - Senior Vice President - Business DevelopmentProfile
Fady Malik - Senior Vice President - Research and Early DevelopmentProfile
Ching Jaw - CFO, Senior Vice PresidentProfile
Andrew Wolff - Senior Vice President - Clinical Research and Development, Chief Medical OfficerProfile
David Cragg - Sr. VP of HRProfile
Bonnie Charpentier - Sr. VP of Regulatory Affairs and ComplianceProfile
Edward Kaye - DirectorProfile
John Henderson - Independent DirectorProfile
Wendall Wierenga - Independent DirectorProfile
Santo Costa - Independent DirectorProfile
Robert Califf - DirectorProfile
Wendell Wierenga - Independent DirectorProfile
Lynne Parshall - Independent DirectorProfile
Sandford Smith - Independent DirectorProfile
Joanna Goldstein - IR Contact OfficerProfile
Diane Weiser - IR Contact OfficerProfile

About Cytokinetics Management Performance

The success or failure of an entity such as Cytokinetics often depends on how effective the management is. Cytokinetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cytokinetics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cytokinetics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Investment(58.61) (63.24) 
Return on Average Assets(0.31) (0.33) 
Return on Average Equity(1.49) (1.53) 
Return on Invested Capital(0.24) (0.27) 
Return on Sales(2.82) (3.05) 
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.
The data published in Cytokinetics' official financial statements usually reflect Cytokinetics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cytokinetics. For example, before you start analyzing numbers published by Cytokinetics accountants, it's critical to develop an understanding of what Cytokinetics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Cytokinetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cytokinetics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cytokinetics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cytokinetics. Please utilize our Beneish M Score to check the likelihood of Cytokinetics' management to manipulate its earnings.

Cytokinetics Workforce Analysis

Traditionally, organizations such as Cytokinetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cytokinetics within its industry.

Cytokinetics Manpower Efficiency

Return on Cytokinetics Manpower

Revenue Per Employee212.7 K
Revenue Per Executive2.9 M
Net Loss Per Employee633 K
Net Loss Per Executive9 M
Working Capital Per Employee322 K
Working Capital Per Executive3.4 M
Today, most investors in Cytokinetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cytokinetics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cytokinetics per employee as a starting point in their analysis.

Per Employee

Cytokinetics Per Employee Growth Over Time

Net Income Per Employee

(633,004)

Share
Cytokinetics Net Income Per Employee is decreasing as compared to previous years. The last year's value of Net Income Per Employee was reported at (586,687)

Revenue Per Employee

212,664

Share
Cytokinetics Revenue Per Employee is increasing as compared to previous years. The last year's value of Revenue Per Employee was reported at 191,902
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.